Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | GASTHER2: trastuzumab for advanced gastric cancer

Rachel Riechelmann, MD, PhD, AC Camargo Cancer Canter, São Paulo, Brazil, outlines the rationale behind the GASTHER2 (NCT04168931) study evaluating trastuzumab for patients with advanced gastric cancer with HER2 positive expression in circulating tumour cells. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).